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Background and Purpose: Intensity-modulated radiation therapy (IMRT) data on hypopharyngeal cancer (HC) are scant. In this 
study, the authors report on early results in an own HC patient cohort treated with IMRT. A more favorable outcome as compared 
to historical data on conventional radiation techniques was expected. 
Patients and Methods: 29 consecutive HC patients were treated with simultaneous integrated boost (SIB) IMRT between 
01/2002 and 07/2005 (mean follow-up 16 months, range 4–44 months). Doses of 60–71 Gy with 2.0–2.2 Gy/fraction were ap-
plied. 26/29 patients were definitively irradiated, 86% received simultaneous cisplatin-based chemotherapy. 60% presented with 
locally advanced disease (T3/4 Nx, Tx N2c/3). Mean primary tumor volume measured 36.2 cm3 (4–170 cm3), mean nodal volume 
16.6 cm3 (0–97 cm3). 
Results: 2-year actuarial local, nodal, distant control, and overall disease-free survival were 90%, 93%, 93%, and 90%, respec-
tively. In 2/4 patients with persistent disease (nodal in one, primary in three), salvage surgery was performed. The mean dose to 
the spinal cord (extension of > 5–15 mm) was 26 Gy (12–38 Gy); the mean maximum (point) dose was 44.4 Gy (26–58.9 Gy).
One grade (G) 3 dysphagia and two G4 reactions (laryngeal fibrosis, dysphagia), both following the schedule with 2.2 Gy per frac-
tion, have been observed so far. Larynx preservation was achieved in 25/26 of the definitively irradiated patients (one underwent 
a salvage laryngectomy); 23 had no or minimal dysphagia (G0–1). 
Conclusion: Excellent early disease control and high patient satisfaction with swallowing function in HC following SIB IMRT were 
observed; these results need to be confirmed based on a longer follow-up period. In order to avoid G4 reactions, SIB doses of 
< 2.2 Gy/fraction are recommended for large tumors involving laryngeal structures.
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IMRT bei Hypopharynxkarzinomen 
Hintergrund und Ziel: Daten zur Behandlung des Hypopharynxkarzinoms (HC) mittels intensitätsmodulierter Radiotherapie 
(IMRT) sind rar. Die Autoren berichten hier über erste eigene Ergebnisse ihres IMRT-Kollektivs konsekutiv behandelter HC-Pati-
enten. Erwartet wurden eine bessere Tumorkontrolle und verbesserte Therapietoleranz bei HC-Patienten nach IMRT gegenüber 
historischen Kollektiven nach konventioneller Radiotherapietechnik. 
Patienten und Methodik: 29 konsekutive HC-Patienten wurden zwischen 01/2002 und 07/2005 mit IMRT mit simultan inte-
griertem Boost (SIB) behandelt. Die mittlere Verlaufsbeobachtung betrug 16 Monate (4–44 Monate). Es wurden Herddosen von 
60–71 Gy mit 2,0–2,2 Gy/Sitzung verabreicht. 26/29 Patienten wurden primär definitiv bestrahlt, 86% erhielten eine simultane 
Cisplatin-basierte Chemotherapie. In gut 60% bestand ein lokal fortgeschrittenes Leiden (T3/4 Nx, Tx N2c/3, Tabelle 1). Das 
mittlere Tumorvolumen betrug 36,2 cm3 (4–170 cm3), das mittlere Lymphknotenvolumen 16,6 cm3 (0–97 cm3). 
Ergebnisse: Die aktuarischen 2-Jahres-Überlebensraten für die Primärtumor-, Lymphknoten- und Fernkontrolle lagen bei 90%, 
93% und 93% (Abbildungen 1a bis 1c); das krankheitsfreie Gesamtüberleben betrug 90%. Vier Patienten zeigten eine Tumorper-
sistenz; in zwei dieser Fälle konnte eine Salvage-Operation durchgeführt werden. Die mittlere Dosis auf das expandierte Myelon 
(Sicherheitssaum > 5–15 mm) betrug 26 Gy (12–38 Gy), die durchschnittliche maximale Punktdosis 44,4 Gy (26–58,9 Gy). 
Bislang entwickelte ein Patient eine Grad(G)-3-Dysphagie und zwei Patienten G4-Reaktionen (Dysphagie, Larynxfibrose); beide 
G4-Ereignisse traten nach 2,2 Gy/Fraktion auf. Bei 25/26 primär bestrahlten Patienten konnte eine Organerhaltung erreicht wer-
den; 23 Patienten sind betreffend Dysphagie beschwerdefrei oder minimal symptomatisch (G0–1). 
Schlussfolgerung: Sehr gute frühe Ergebnisse hinsichtlich der Krankheitskontrolle und eine hohe Patientenzufriedenheit in 
Bezug auf die Schluckfunktion wurden beobachtet; diese Resultate müssen mit einer längeren Verlaufsbeobachtung bestätigt 
werden. Einzeldosen ≥ 2,2 Gy werden im Hinblick auf die beobachteten G4-Reaktionen bei ausgedehnten Tumoren mit Befall 
laryngealer Strukturen empfohlen. 
Schlüsselwörter:  Hypopharynxkarzinom · IMRT · SIB · Strahlentherapie-induzierte Dysphagie
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Introduction 
Locoregional disease control rates of approximately 40–70% 
[2, 3, 6, 11, 15, 17, 18, 20, 21, 24, 26, 27, 30] or even less [4, 9, 
13] are reported for hypopharyngeal cancer (HC) patients re-
ceiving three-dimensional conventional radiation therapy 
(3DCRT) ± chemotherapy, while late-term dysphagia rates 
range between 40% and 75% in the majority of published ar-
ticles [1, 6, 19, 20, 28]. The main challenge in conventional ir-
radiation of HC is an appropriate dose coverage mainly to the 
dorsal aspect of the tumor and the boost planning target vol-
ume (PTV1), respectively, which is often close to or overlaps 
the spinal cord in the lateral-beam projection used for 3DCRT. 
Dorsal volume compromises in favor of the spinal cord as the 
organ at highest risk are a frequent consequence of this fact. 
For HC patients the feasibility of “horse shoe”-like dose 
distribution is an advantage that was expected to translate into 
improved clinical outcome due to uncompromising target vol-
ume coverage. 
Clinical outcome in HC following intensity-modulated 
radiation therapy (IMRT) was prospectively assessed. 
Patients and Methods 
Patients 
29 consecutive HC patients received IMRT between January 
2002 and July 2005. Mean follow-up time was 16 months (range 
4–44 months). Patients’ mean age was 60.8 years (34–87 years); 
the gender ratio was 1 : 5 in favor of men. TN stages are shown 
in Table 1. 
86% of the patients (n = 25) were irradiated definitively, 
and four postoperatively. 86% (n = 25) received simultaneous 
cisplatin-based chemotherapy with 40 mg/m2/week. 21/25 pa-
tients (83%) tolerated four to six cisplatin cycles. 
Mean primary tumor volume measured 36.2 cm3 
(4–170 cm3), mean lymph node volume (N+ only) 24.8 cm3 
(1–97 cm3). Mean total gross tumor volume (GTV) was 52 cm3 
(5–173 cm3). 
Methods 
IMRT Schedules 
Simultaneous integrated boost (SIB) doses between 60 and 
71 Gy (five fractions/week) with 2.0 (n = 8), 2.11 (n = 17), and 
2.2 Gy (n = 4)/fraction to the boost volume (planning tar-
get volume, PTV1) were applied. Doses to the elective neck 
areas (PTV2) ranged between 54 and 56 Gy with doses of 
1.64–1.8 Gy/session. 
Mean total treatment time was 45.4 days (32–58 days). 
Planning Computed Tomography (Planning CT) 
Planning CT data (Somatom Plus 4, Siemens, Erlangen, Ger-
many) were acquired with a slice thickness of 2–3 mm and no 
interslice gap throughout the whole sequentially acquired re-
gion of interest. Patients were immobilized in a commercially 
available thermoplastic mask. 
In patients with postoperative irradiation, GTVs were 
drawn slice by slice in the planning CT, based on diagnostic 
preoperative magnetic resonance images (MRIs) and positron 
emission tomography (PET) CTs, which were available for all 
patients [10]. In the majority of the definitively irradiated pa-
tients, fused “PET-planning CTs” (Siemens AG, Erlangen, 
Germany, and Discovery LS, GE Medical Systems, Wauke-
sha, WI, USA) were performed. 
Treatment-Planning Systems 
Contouring and plan optimization were performed on a Var-
ian treatment-planning system (Eclipse®, Version 7.3.10, Var-
ian Medical Systems, Hansen Way, Palo Alto CA, USA).
Delineation of Planning Target Volumes (PTVs) 
Definitions: GTV with a margin of 10–15 mm was included in 
the SIB volume (PTV1, 60–71 Gy).
Elective lymph node regions (PTV2, 50–57 Gy) level 2–5 
were included bilaterally.
Dose constraints for normal tissues/organs at risk outside 
PTVs: 
•  Spinal cord: maximum dose (Dmax) < 45 Gy, mean dose 
(Dmean) < 35 Gy (cord outlined with a margin > 5–10 mm, 
with > 10 mm at the ventral aspect).
•  Parotid glands were spared to the degree possible without 
compromising target volume coverage: Dmean < 26 Gy (par-
tial volume to be spared was outlined).
•  Oral cavity outside the PTV (contouring included the man-
dible, maxillary bone, and oral vestibulum): Dmean < 35 Gy.
• Nuchal tissue: Dmean < 45 Gy.
Radiation 
Irradiation was done by 6-MV photon beams on a Varian lin-
ear accelerator using the sliding-window technique. The tech-
nical solution of choice was a five-field equiangular arrange-
ment (“class solution”). 
Patient alignment was checked by portal imaging; devia-
tions of > 3 mm were corrected before treatment. 
The dose homogeneity within the PTV1 was aimed to be 
in close accordance with the RTOG guidelines: 
•  The dose was normalized to the mean dose in PTV1 which 
corresponded, in the majority of cases, approximately to the 
95% dose level in that volume. 
Table 1. TN stage distribution in 29 hypopharyngeal cancer patients. 
Tabelle 1. TN-Stadien-Verteilung im untersuchten Kollektiv von 29 Pa-
tienten mit Hypopharynxkarzinom. 
 N0 N1 N2a N2b N2c N3 Total
T1 0 0 1   0 0 1   2    
T2 3 0 1   8 2 0 14    
T3 1 1 1   2 1 0   6    
T4 1 2 0   2 2 0   7    
Total 5 3 3 12 5 1 29
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•  The prescription dose was based on the isodose which en-
compasses at least 95% of the PTV. 
• No more than 
  –  20% of any PTV received > 110% of its prescribed 
dose, 
  – 1% of the PTV1 received < 93% of its prescribed dose, 
  –  1% or 1 cm3 of the tissue outside the PTV received > 110% 
of the PTV1 dose. 
Clinical Quality Assurance (QA) 
Follow-up. Patients under treatment were clinically assessed 
at weekly intervals, and at 2 weeks and 2 months after comple-
tion of treatment. 
6 weeks after completion, patients were also seen in the 
joint clinics of the Department of Head & Neck Surgery, then 
every 2–3 months in the first 2 years, 3- to 6-monthly in the 3rd 
year. Suspect findings were substantiated with CT-PET, sus-
pect lymph nodes by needle aspiration and/or biopsy, respec-
tively. 
The swallowing function was assessed by semistructured 
interviews (ability to swallow liquid, soft and solid food, per-
sonal comfort [when eating out and whether patients enjoy 
their food]). 
QA with respect to posttreatment events. Isodose plans of 
patients who experienced grade (G) 3/4 late-term effects were 
reviewed at the radiation-planning work station, in order to 
check local dose distributions.
QA with respect to quality of life (QoL). Toxicity was as-
sessed based on SOMA-LENT and RTOG/EORTC Radia-
tion Morbidity Score. For simplification, G3 or 4 late reactions 
were termed “G3/4” reactions.
Statistics 
The StatView® program Version 4.5 was used for calculation 
of Kaplan-Meier survival curves.
Results 
Tumor Response and Survival (Figures 1a to 1c) 
After a mean follow-up of 16 months (4–44 months), the actu-
arial local (LC), nodal (NC), distant control (DC), and overall 
disease-free survival at 2 years were 90%, 93%, and 93%, re-
spectively. 90% of the patients were alive with no evidence of 
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Figures 1a to 1c. a) Actuarial 2-year local disease-free survival: 90%. 
b) Actuarial 2-year regional disease-free survival: 93%. c) Actuarial 
2-year distant disease-free survival: 93%. 
Abbildungen 1a bis 1c. a) Lokale Tumorkontrolle: 90% aktuarisches 
2-Jahres-Überleben. b) Nodale Kontrolle: 93% aktuarisches 2-Jahres-
Überleben. c) Fernmetastasenkontrolle: 93% aktuarisches 2-Jahres-
Überleben. 
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Figure 1a – Abbildung 1a        Figure 1b – Abbildung 1b 
Figure 1c – Abbildung 1c 
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disease (ANED) at the time point of data analysis (November 
2005). In three patients with definitive IMRT, tumor persis-
tence was observed. In one of these three patients with a large 
persistent tumor of 115 cm3, simultaneous metastases occurred 
a few weeks after treatment completion. The second patient 
who developed distant disease remained locoregionally con-
trolled. Successful salvage surgery of the primary was feasible 
in one of these three patients. 
In one patient with nodal persistence, salvage surgery was 
successfully performed 1 year earlier. 
No locoregional tumor recurrences were observed up to 
now. 
Toxicity 
Acute Reactions 
No G4 acute toxicity occurred, and no interruptions of radio-
therapy were required due to radiation-related side effects 
(elongated total treatment time due to radiotherapy-indepen-
dent intercurrent events in two patients). Skin and mucosal 
acute reactions were mild to moderate and limited to the 
high-dose area (six G3, 13 G2 mucositis).
A feeding tube was inserted in nine patients (30%). The 
average body weight loss from initial pretreatment value to 
the end of irradiation was 7% (19% loss up to 11% gain); 
mean loss was 3% in patients with a feeding tube and 9% in 
the subgroup without tube, respectively.
Late Reactions 
In three patients G3/4 late-term effects were observed: one 
laryngeal fibrosis G4 (no increased dose was delivered to the 
laryngeal region), one G4 dysphagia (good voice, but unable 
to swallow liquids). In both cases laryngeal and infralaryngeal 
structures were infiltrated by the tumor. One patient devel-
oped dysphagia G3 following SIB2.11 to 69.6 Gy.
Laryngeal preservation was maintained in all 23 locally 
controlled patients who underwent definitive IMRT, an ulti-
mate organ preservation in 96% (26/27). 24/27 controlled 
patients had no or minimal dysphagia (G0–1) at the time of 
last visit, two had a persisting G3 and G4 dysphagia, respec-
tively. 
The mean body weight loss 1 year after treatment com-
pletion was 3.3% (+11% to –11%). 
The mean dose to the (expanded) spinal cord was 26.4 Gy 
(12–38 Gy); mean maximum (point) dose was 44.4 Gy 
(26–57 Gy). No spinal cord toxicity is expected. 
Dose-Volume Coverage 
Doses of > 110% of prescribed total dose were delivered to a 
mean of 0.3% (0–2%) of PTV1. A mean of 8.2% (0–13%) of 
PTV1 received < 95% of the prescribed dose.
All treatment plans were analyzed with respect to the 
dose-volume compromises which would have been made, if 
3DCRT techniques had been performed. In this technique, a 
“compromise” was made, if the photon-electron field match-
ing line across primary or nodal GTV in order to spare the 
spinal cord, or if the GTV/PTV1 was not adequately covered, 
or if the deep aspect of large nodal disease was insufficiently 
covered by electrons. In 9/29 cases such a “compromise” could 
be avoided with IMRT [16, 25]. 
Discussion 
To our knowledge this is the first analysis of a single-institu-
tion HC series irradiated with IMRT. 
Improved early outcome in HC following IMRT com-
pared to 3DCRT, with high locoregional control and dis-
ease-free survival rates of 90% each, was found in a cohort 
with definitive IMRT in the majority of cases. All four locore-
gional failures presented as tumor persistence inside the 
high-dose PTV1. However, the follow-up is still too short to 
draw final conclusions from presented disease outcome. 
There is a single report on outcome in HC after IMRT by 
Eisbruch et al., who described a 3-year locoregional control 
rate of ~ 77% in twelve HC patients [5]. 
In historical HC series, the 3- to 5-year disease-specific 
survival rates range from ~ 40 up to 70% [2, 3, 6, 11, 15, 17, 18, 
20, 21, 24, 26, 27, 30]; Garden et al. [8] found a 2-year LC of 
89% and 77% for HC stage T1 and T2, respectively, in 82 HC 
patients; Nakamura et al. [23] reported a 5-year disease-spe-
cific survival of 90% in 43 stage I/II HC patients. 
Our early results confirm earlier data on 3DCRT of pha-
ryngeal wall tumors published by Fein et al. back in 1993 [7]. 
These authors found an improved outcome in 49 patients in 
whom the dorsal field border of the boost fields was placed at 
the anterior aspect of the spinal cord, versus 50 patients in 
whom the dorsal boost field border was halfway across the 
vertebral bodies (equal 2-year LC of 100% in T1 stages, statis-
tically significant difference in T2 stages with 100% vs. 57%, 
73% vs. 46% in T3, and 75% vs. 29% in T4, respectively). 
With average doses to the expanded spinal cord of mean/
maximum 26/44 Gy in our cohort, no increased cord risk was 
taken. 
Johansson et al. [14] performed plan comparisons for 
protons, IMRT, and 3DCRT in five HC patients. They re-
ported that 3.6%, 10.9%, and 70.3% of the spinal cord vol-
ume received > 50% of prescribed doses, and cord maximum 
doses of approximately 43, 46, and 44 Gy, respectively. In ad-
dition to the absolute mean dose reduction with IMRT tech-
nique, spinal cord exposure (as most organs [20, 22, 29]) in 
IMRT is also reduced from a radiobiological point of view, as 
the dose/fraction is about one quarter to one third of the pre-
scribed dose. 
Laryngopharyngeal organ preservation and organ func-
tion in our cohort were excellent with > 90%. 
Organ preservation following definitive conventional ra-
diochemotherapy has been reported by several groups and 
ranges between about 40% and up to 75% [1, 6, 12, 19, 20, 28, 
30]. Huguenin et al. reported dysphagia and laryngitis G3/4 
late reaction rates of ~ 22% and 3%, respectively, in a pro-
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spective study of 224 patients with 25% hypopharyngeal and 
~ 16% laryngeal tumors [12]. 
Samant et al. [26] evaluated 25 patients following radio-
chemotherapy for advanced pyriform sinus carcinoma and 
found an organ preservation rate of 88%, with 90% of pa-
tients having a satisfactory voice and 70% being able to swal-
low 1 year after treatment. 
The two relevant late-term effects observed in our series 
developed after an exposure of 66–68 Gy with 2.2 Gy per ses-
sion (SIB2.2) to a large GTV involving the larynx and cranial 
esophagus. 
Conclusion 
Improved early locoregional outcome with excellent preser-
vation of swallowing function was found in HC patients treat-
ed with IMRT compared to historical reports; these results 
need to be confirmed based on a longer observation time. 
SIB using 2.2 Gy per fraction is not recommended for HC 
involving laryngoesophageal structures. 
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